Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6

Hideaki Ishikawa1, Naohiro Tsuyama, Saeid Abroun

  • 1Department of Bio-Signal Analysis, Applied Medical Engineering Science, Graduate School of Medicine, Yamaguchi University, 1-1-1 Minami-kogushi, Ube, Yamaguchi 755-8505, Japan.

Blood
|March 6, 2002
PubMed

Insights

Interleukin-6 (IL-6) promotes multiple myeloma cell proliferation only when src family kinases are activated independently of IL-6. This src family kinase activation, linked to CD45 expression, is essential for IL-6-driven myeloma cell growth.

Area of Science:

  • Oncology
  • Cell Biology
  • Immunology

Background:

  • Interleukin-6 (IL-6) signaling pathways, including STAT3 and ERK1/2, are crucial for cellular responses.
  • Multiple myeloma is characterized by the dysregulation of cell proliferation pathways.

Purpose of the Study:

  • To investigate the specific intracellular signals and cellular context required for IL-6-induced proliferation in multiple myeloma.
  • To elucidate the role of src family kinases and CD45 expression in IL-6-mediated myeloma cell growth.

Main Methods:

  • Activation of STAT3 and ERK1/2 pathways in response to IL-6.
  • Assessment of IL-6 effects on CD45+ and CD45- myeloma cells.
  • Inhibition of src family kinases using antisense oligodeoxynucleotides and selective inhibitors.

Main Results:

  • IL-6 enhanced proliferation only in CD45+ myeloma cells with pre-existing IL-6-independent src family kinase activation.
  • STAT3 and ERK1/2 activation by IL-6 occurred in both CD45+ and CD45- cells.
  • Suppression of IL-6-induced proliferation in CD45+ U266 cells using Lyn-specific antisense or src kinase inhibitors.

Conclusions:

  • STAT3 and ERK1/2 activation alone are insufficient for IL-6-induced myeloma cell proliferation.
  • Src family kinase activation, associated with CD45 expression, is a prerequisite for IL-6-driven myeloma cell proliferation.
  • IL-6-induced proliferation in myeloma is highly dependent on the cellular context and specific signaling pathways.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...